Alvotech ( NASDAQ:ALVO ) just reported some strong earnings, and the market reacted accordingly with a healthy ...

As recently as March, the FDA approved the IL-23 inhibitor guselkumab (Tremfya, Johnson & Johnson/Janssen) for patients with Crohn’s disease, offering both IV and subcutaneous induction options.

Yahoo Finance went to the 2025 World Economic Forum (WEF) in Davos, Switzerland, to hear what global and corporate leaders have to say about the future of their respective industries and the ...

FDA approves Teva and Alvotech's Selarsdi as an interchangeable biosimilar to Stelara, supporting the treatment of multiple chronic inflammatory diseases. Vandana Singh Regeneron Shares Are Up ...